Pembrolizumab (Keytruda) for Mismatch Repair Deficient Colorectal Cancer - Details

( Last Updated : February 25, 2020)

Generic Name:

Pembrolizumab

Manufacturer:

Merck Canada Inc.

Brand Name:

Keytruda

Project Line:

Reimbursement Review

Details

Tumour Type:

Gastrointestinal

Indications:

Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy.

Review Status:

Not Filed

Clarification:

CADTH is unable to recommend reimbursement because a submission was not filed by the manufacturer.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.